Summary

• Pharmaceutical companies developing a vaccine for Covid-19 have announced that they would ensure the safety and effectiveness of their vaccine candidates before seeking the government’s approval.
• Despite the race to win the market launch of the Covid-19 vaccine, the competitors have remarkably joined hands torestore confidence of the public that the exigency to develop the vaccine shots would not give any concession to scientific and regulatory protocols.
• Some of these companies include big names like Moderna Inc, Johnson & Johnson (J&J), and
• The vaccine developers believed this joint pledge would assist in guaranteeing confidence of the public in the Covid-19 vaccines.

Many global pharmaceutical companies that are engaged in developing a vaccine for Covid-19 have announced that they would ensure the safety and effectiveness of their vaccine candidates before seeking the government’s approval. In a remarkable move, several companies from the US said that they would come together to issue a pledge against the government’s nod on their vaccine candidates. In the race to win the market launch of the Covid-19 vaccine, the competitors have joined hands torestore confidenceof the public that the exigency to develop the vaccine shots would not give any concession to scientific and regulatory protocols.

Some of these companies include big names like Moderna, Johnson & Johnson (J&J), and Pfizer that have been in news over recent past regarding their vaccine shots for the respiratory illness of Covid-19, caused by the novel coronavirus – SARS COV2.

The pharmaceutical companies would be taking an oath to prioritise the safety and well-being of the larger healthy population who would be vaccinated to protect against catching the highly infectious Covid-19 disease. The pharmaceutical and biotech giants also stated that they would maintain all the required scientific and ethical norms in their procedures to carry on the clinical studies and human trials, besides the manufacturing processes.

The pharmaceutical majors leading the development of a potential vaccine as a safeguard against the Covid-19 infection informed that the joint pledge is expected to be issued as early as the week starting on 7 September 2020. The firms are working on a joint draft statement that would soon be finalised. The development around the pledge is seen in the lights of increased worries arising on the safety and effectiveness of a potential vaccine for the respiratory infection amid mounting political weight ahead of the United States (US) presidential elections, scheduled to be held in November 2020.

Kayleigh McEnany, press secretary at the White House said on 3 September 2020 that despite the stakes being high for Donald Trump, the present US president who is contesting against Joe Biden, the former vice president and the democratic presidential nominee for the 2020 presidential election,the US health regulator is not under any political pressure to hurriedly approve a vaccine for Covid-19 infection.AstraZeneca Plc, Moderna, and Pfizer are known to lead the race to develop the vaccine for COVID-19 infection as their respective candidates are currently in late-stage clinical trials.

The vaccine developers said in a draft statement that they believed this joint pledge of theirs would assist in guaranteeing confidence of the public in the Covid-19 vaccines that would be launched in the market only after a government approval. The companies highlighted that the approvals are based on a strict evaluation system and it is important to follow the meticulous scientific and regulatory standards.

Also read: When Will A Covid-19 Vaccine Be Available In Britain?

Also read: Swedish model during the coronavirus pandemic

Amid the rising fears that any regulatory nod might arrive prior to a vaccine candidate being completely checked by the authorities, it is the duty of the scientists and industry leaders to assure the public regarding their commitment to the safety of their products. The draft statement stressed on the fact that the vaccine makers would apply for government approvals only after they reach a substantial proof on safety and efficiency gained from Phase 3 trials that are carried under the supervision of the Food and Drug Administration (FDA). These trials are conducted to gather evidence that the vaccine would decrease the rates of symptomatic Covid-19 disease as compared to the individuals who are not vaccinated.

Several drug makers have started their phase 3 trials and are awaiting the outcome in coming months to apply for the government nod or probable authorisation for emergency usage of their shots. In end-August 2020, the Centers for Disease Control and Prevention, likely to be responsible for vaccine distribution in the US, informed the US states that by November 2020 they could start the Covid-19 vaccination drive. A FDA meeting of external experts to deliberate on Covid-19 vaccine was scheduled for later part of October 2020. The FDA has stated that it would approve only those vaccines that are 50 per cent effective compared with a placebo.

It is to be recalled that the authorisation of convalescent plasma as a treatment for Covid-19 illness and emergency usage of hydroxychloroquine, an anti-malaria drug has already faced severe accusation and criticism for allowing to be used without a sufficient placebo-controlled examination.

Developments at the pharmaceutical companies- Pfizer and Merck

Pfizer expected that it would generate substantial statistics by October 2020 to file for an emergency-use authorization in case its studies bring positive results. The company reiterated at a trade body event organised by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)that it would not come up with requests for any authorisation or approval until it was sure that the vaccine met all the safety and effectiveness criteria. Pfizer mentioned that the drug maker has not observed any pressure from the political corners for launching a vaccine and it would never bypass any necessary standards or protocols.

Speaking at the forum hosted by IFPMA, Merck & Co, another leading pharmaceutical major commented that though there is an urgency of coming up with a potential vaccineamid the ongoing fight against the coronavirus pandemic, but the company would focus on safety issues under any situation. In July 2020, Merck planned to begin the initial human trial for one of its experimental vaccines by end of September 2020. A second vaccine candidate by the company is expected to enter testing stage only by end-2020.

AstraZeneca's vaccine candidate could get FDA nod for emergency use by October

The Covid-19 vaccine from the British pharmaceutical company, AstraZeneca plc (LON: AZN) is likely to receive approval from the FDA by October 2020, before the scheduled US presidential elections. The trump administration is looking for ways to facilitate emergency use authorisation in October for the vaccine maker. The authorisation is likely to be based on a study involving 10,000 volunteers in the UK as compared to requirement from the US for a safe vaccine to be tested on 30,000 people. The company is likely to complete its Phase 3 trials in November or December this year. AstraZeneca is developing the vaccine along with the Oxford University, besides having a deal with the Serum Institute of India for supplying the vaccine to developing countries, European Union (EU), and Latin American countries.

Also read: 5 Vaccine Stocks Doing Well in the UK

Also read: USFDA Approval for AstraZeneca Vaccine Bring Cheer at FTSE 100 as well

Views from the experts on early timeframe of Covid-19 vaccine

Many experts including leading virologists and vaccine institutions on the panel of the FDA vaccine-advisory committee observed that October 2020 would be a short timeframe to gather enough data that would show the efficiency of the Covid-19 vaccines that are in late-stage trials or testing. Many experts agreed that a safer time frame seemed not before early 2021.

MoncefSlaoui, an ex-GlaxoSmithKline PLC official and adviser of the White House Covid-19 vaccine-development program has reportedly stated that he would put his papers in case the Trump administration hurried an emergency-use authorisation.

The Biotechnology Innovation Organization, another trade group, came up with an open letter for the pharmaceutical industry and stated the doctrine regarding development of treatment and vaccine for Covid-19 infection, besides evaluating the public release of statistics and insights on the ongoing clinical trials. In addition to the guidelines for the industry, the letter pointed out that any political reflection needs to be kept aside in times of the pandemic.

Also read:Early Vaccine Hopes May Put A Life to The Dried Dividends for The UK Investors

Also read:British Government Signs Up for another 90 Million Doses of Covid-19 Vaccine

Lung cancer treatment co-developed by Roche and Blueprint gets FDA Approval

In another recent development from the pharmaceutical industry that grabbed headlines on government approval, Roche Holding AG informed on 4 September 2020 that a potential treatment that it developed along with Blueprint Medicines Corp from Cambridge got the approval from the FDA. The treatment is for patients suffering from a type of non-small cell lung cancer (NSCLC).

The drug namedGavreto from the two companies is an oral medicine has been prepared to selectively target the RET-altered cancers that have mutations and are responsible for increasing the growth of the tumor. There is an FDA-approved test to detect the tumor growth in patients. Blueprint Medicines informed that the medicine would be marketed together by the two companies in the US and would be made available in about seven days.

It is to be recalled that in July 2020, Roche struck a deal with Blueprint Medicines, which was worth up to $1.7 billion for rights to Gavreto that awaited the government nod to be used for treating advanced RET mutant and RET fusion-positive thyroid cancers. As per Roche, the Swiss drug company, just 1-2 per cent of the patients with NSCLC have RET fusions.

Conclusion

The coronavirus pandemic has increasingly brought the spotlight on pharmaceutical companies as they have been working to develop a potential vaccine candidate to prevent the risk of infection in healthy population of the world. The lockdown and consequent public health advisory on social distancing norms have brought severe economic crisis across the world and both people and government are looking to see a vaccine soon so that economic recovery is expedited and healthy world population once again engage in meaningful economic and social activities. Given these exigencies and regular updates from the vaccine makers on trials, there has been a fear among the public that safety and effectiveness of the vaccine would be compromised amid the race to be the first company to come out with a vaccine. The pledge from the leading vaccine makers is seen as an assurance to the public that the companies would prioritise the safety and effectiveness before getting the government approval to launch the vaccine for mass usage.